*Please read the full notice and disclaimer at the bottom of this page.

Listen to Fr. Emmanuel live on May 13, 2019, speaking to the crew of Benzinga TV about the US-China trade war and the following securities:

• Bed Bath and Beyond (NASDAQ:  BBBY)
• Kraft Heinz (NASDAQ: KHC)
• Apple (NASDAQ: AAPL)
• Geospace Technologies (NASDAQ: GEOS)
• Uber Technologies (NYSE:  UBER)

Watch the full interview below or click here.

*Please read the full notice and disclaimer at the bottom of this page.

It's just unsustainable, completely unsustainable... you can not borrow money to increase a shareholder deficit... they're extracting wealth from their owners and they're doing it using leverage,”

...they [Geospace] have a highly diversified business now... the business is extremely sound... there's an enormous margin of safety... I think we're right, I think we'll be proven right and I think the return will be tremendous..."

Since making these comments, Geospace Technologies shares have risen nearly 54 percent (vs.12 percent for the S&P 500 Total Returns Index) and have recently hit a new 52-week high.  

*Please read the full notice and disclaimer at the bottom of this page.

Bed Bath and Beyond (NASDAQ: BBBY) has surged almost 49 percent since December 28, 2018, when Fr. Emmanuel spoke live to the crew of Benzinga TV about the company, saying:

"It's [BBBY] now between $10 and $11 per share, pretty extraordinary business if you think about it, about a 1.4 billion market cap., just over a billion of that in cash, and then a company that threw off $750 million in free cash flow... in the last twelve months... growing revenues for a very long time, an iconic American retailer... they're paying almost a 5% dividend... for the record I think it's worth more like $40 or $50 and I wouldn't be surprised if in the next year we see it return to that sort of valuation... "

In the roughly six weeks since the interview, the stock has risen approximately 49 percent vs. 11 percent for the S&P 500 Total Returns Index:

*Please read the full notice and disclaimer at the bottom of this page.

Bed Bath and Beyond (NASDAQ: BBBY) surged as much as 25 percent in after-hours trading today, January 09, 2019.  On December 28, 2018, Fr. Emmanuel spoke live to the crew of Benzinga TV about the company:

"It's [BBBY] now between $10 and $11 per share, pretty extraordinary business if you think about it, about a 1.4 billion market cap., just over a billion of that in cash, and then a company that threw off $750 million in free cash flow... in the last twelve months... growing revenues for a very long time, an iconic American retailer... they're paying almost a 5% dividend... for the record I think it's worth more like $40 or $50 and I wouldn't be surprised if in the next year we see it return to that sort of valuation... "

In the roughly six trading days since the interview, the stock has risen approximately 24 percent vs. 3.99 percent for the S&P 500 index:

*Please read the full notice and disclaimer at the bottom of this page.

Listen to Fr. Emmanuel live on December 28, 2018, speaking to the crew of Benzinga TV about recent market volatility, fraud, macroeconomic issues and the following securities:

• Bed Bath and Beyond (NASDAQ:  BBBY)
• Apple (NASDAQ: AAPL)
• Facebook (NASDAQ: FB)
• Tesla (NASDAQ: TSLA)
• Geospace Technologies (NASDAQ: GEOS)

Watch the full interview below or click here.

"καὶ μὴ συγκοινωνεῖτε τοῖς ἔργοις τοῖς ἀκάρποις τοῦ σκότους, μᾶλλον δὲ καὶ ἐλέγχετε,"  Ephesians 5:11.  Read about Fr. Emmanuel's extraordinary dust-up with the SEC here and here as shares of Ligand Pharmaceuticals (NASDAQ: LGND) continue to plummet. 

Watch Fr. Emmanuel's November 2017 talk with global business and political leaders on Theology and short selling here:

"Short sellers — investors who bet against companies — get a bad rap, but research suggests they help keep markets running smoothly." - NPR

So much more we would like to have added, but couldn't fit in a Motion to Dismiss with a 20-page limit.   For more background see Fr. Emmanuel's September 12, 2018 release regarding the SEC action here.  To view the full motion to dismiss, click here or view on Scribd below.

...more than 40% and more than $111 per share in October 2018 alone"

In reference to Ligand's share price plummeting
Motion to Dismiss, October 25, 2018

The SEC’s allegation is flat-out wrong and exposes a complete lack of understanding of the most elementary principles of accounting"

In reference to The SEC allegations
Motion to Dismiss, October 25, 2018

Ligand is only one market correction away from collapse which will leave investors and employees defenseless."

Fr. Emmanuel Lemelson, July 13, 2018
Letter to Congress 

DEFENDANTS’ MEMORANDUM OF L... by on Scribd

On July 27, 2018 Ligand was sued for $3.8 billion by investors in eight bond funds, including Citadel,¹ this followed multiple class-action lawsuits, alleging securities fraud, filed against Ligand beginning in 2016.²

On July 17, 2018, Fr. Emmanuel released a letter he provided members of The U.S. House Committee on Oversight and Government Reform, The U.S. Senate Special Committee on Aging and the SEC Office of the Inspector General, further outlining extensive alleged abuses of accounting, pharmaceutical reimbursement and classification guidelines and regulations by Ligand Pharmaceuticals. In the letter, Lemelson urged the Committees in both the House and the Senate to commence an investigation into these alleged abuses, as well as the Securities and Exchange Commission’s (SEC) failure to stop them.

Lemelson's full July 13, 2018 letter to Congress is available online here

His December 2016 letter to the U.S. Senate Special Committee on Aging, regarding the company, is available online here

To read Fr. Emmanuel's original 2014 reports on Ligand Pharmaceuticals, click here and here

¹ Read more online here

² The lawsuits made substantially the same claims as The Lemelson Capital Management, LLC 2014 reports.

I would like to say more, but need to leave room for the judicial process to do its job - Fr. E.

Fr. Emmanuel Lemelson Responds to SEC Charges

MARLBOROUGH, Mass., September 12, 2018 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson, the Chief Investment Officer of Lemelson Capital Management, today responded to a civil complaint filed by the United States Securities and Exchange Commission in the United States District Court of Massachusetts, Boston Division. In its complaint, the Commission alleges that Fr. Emmanuel engaged in violations of the federal securities laws in connection with transactions in the securities of Ligand Pharmaceuticals Inc. (NASDAQ: LGND), a U.S.-based publicly-traded pharmaceutical company.

This matter, the likes of which the Commission has never previously brought, has no merit and amounts to a gross abuse of prosecutorial discretion. Fr. Emmanuel intends to vigorously contest the allegations and to demonstrate that the Commission’s claims are contaminated by the misconduct of the staff of its Enforcement Division.

“The Commission chose to bring this case based upon its Enforcement staff’s personal feelings and facts be damned, win-at-any-cost ambitions which have allowed it to ‘make up the rules’ as they go along. The government's claims are false and will be proven to be so” Lemelson said.

“The action is an effort to destroy the reputation of a whistleblower, who provided factually accurate and critical information concerning an alleged massive multi-year accounting fraud at Ligand Pharmaceuticals,” Lemelson added.

On July 27, 2018 Ligand was sued for $3.8 billion by investors in eight bond funds, including Citadel,¹ this followed multiple class-action lawsuits, alleging securities fraud, filed against Ligand beginning in 2016.²

“We are looking forward to defending this matter, exploring the possibility of bringing a complaint against the SEC and to setting a precedent that will prevent this sort of meritless action from being brought in the future,” Lemelson continued.

Separately, Fr. Emmanuel recently released a letter he has provided members of The U.S. House Committee on Oversight and Government Reform, The U.S. Senate Special Committee on Aging and the SEC Office of the Inspector General, further outlining extensive alleged abuses of accounting, pharmaceutical reimbursement and classification guidelines and regulations by Ligand Pharmaceuticals. In the letter, Lemelson urged the Committees in both the House and the Senate to commence an investigation into these alleged abuses, as well as the Securities and Exchange Commission’s (SEC) failure to stop them.

Lemelson's full July 13, 2018 letter to Congress is available online here

His December 2016 letter to the U.S. Senate Special Committee on Aging, regarding the company, is available online here

About Rev. Fr. Emmanuel Lemelson:

Rev. Fr. Emmanuel Lemelson is the Chief investment officer of Lemelson Capital Management, LLC a Massachusetts based investment management firm

For more information, see:  https://www.lemelsoncapital.com/

For further information, please contact:

Lemelson Capital Management, LLC 
Investor and Media Relations 
Telephone: 508-630-2281

Source: Lemelson Capital Management, LLC

¹ Read more online here

² The lawsuits made substantially the same claims as The Lemelson Capital Management, LLC 2014 reports.

Just fourteen days after Rev. Fr. Emmanuel published an open letter to Congress alleging a multi-year accounting and securities fraud at Ligand Pharmaceuticals (NASDAQ: LGND) the company has been sued for $3.8 billion by investors (eight bond funds, including Citadel), who accused the biotech company of unfairly changing the terms of a bond agreement.

According to the complaint, Ligand unfairly modified the agreement and never filed the required amendment with the U.S. Securities and Exchange Commission (SEC) to deny investors more than $3.8 billion in payouts.  If the investors prevail the company could be forced into bankruptcy. 

On August 14, 2014 Lemelson Capital Mangement, LLC published a report outlining the risk of the bond offering, questioned the representations made by the company, and pointed out that the offering may eventually lead to solvency risks.  The complaint further affirmed Lemelson Capital's 2014 reports, stating,“As of 2014, Ligand remained a venture struggling to create a sustainably profitable business model”.

Lemelson's full July 17, 2018 letter to Congress is available online here and a December 2016 letter to the U.S. Senate Special Committee on Aging, regarding the company, is available online here.

The case is AG Oncon LLC v. Ligand Pharmaceuticals Inc., Del. Ch., No. 2018-0556, complaint 7/27/18.

Investors Sue Ligand Pharma... by on Scribd

Rev. Fr. Emmanuel Lemelson ... by on Scribd